Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Dr. Marc Nazare	06/22/2004
Dr. Volkmar Wehner	06/27/2004
Dr. David William Will	08/25/2004
Dr. Kurt Ritter	06/24/2004
Dr. Matthias Urmann	06/24/2004
Dr. Hans Matter	06/23/2004

RECEIVING PARTY DATA

Name:	Aventis Pharma Deutschland GmbH
Street Address:	Brüningstrasse 50
City:	Frankfurt am Main
State/Country:	GERMANY
Postal Code:	D-65929

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	10849089

CORRESPONDENCE DATA

Fax Number: (908)231-2626

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 908-231-3582

Email: robin.inman@aventis.com

Correspondent Name: Jiang Lin Address Line 1: Route 202-206 Address Line 2: Mail Code: D303-A

Address Line 4: Bridgewater, NEW JERSEY 08807

NAME OF SUBMITTER: Robin J. Inman

> **PATENT REEL: 015154 FRAME: 0302**

500007447

Total Attachments: 1

source=DEAV2003-0033 US NP Assignment#page1.tif

PATENT REEL: 015154 FRAME: 0303

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Marc Nazaré, Felix-Lahnstein-Str. 4b, 65510 Idstein, Germany
- 2) Dr. Volkmar Wehner, Lindenstraße 1, 97657 Sandberg, Germany
- 3) Dr. David William Will, Kirchstrasse 21, 65830 Kriftel, Germany
- 4) Dr. Kurt Ritter, Gutzkowstr. 2, 60594 Frankfurt am Main, Germany
- 5) Dr. Matthias Urmann, Im Sylvaner 4b, 65760 Eschborn, Germany
- 6) Dr. Hans Matter, Feldbergring 37, 63505 Langenselbold, Germany

The inventors are citizens of: 1) - 2) GERMANY; 3) UNITED KINGDOM; 4) - 6) GERMANY

hereby sell, assign, and transfer unto AVENTIS PHARMA DEUTSCHLAND GMBH, a corporation organized under the laws of GERMANY, located at D-65929 Frankfurt am Main, GERMANY,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 10/849,089

May 19, 2004

entitled: Azaindole-derivatives as factor Xa inhibitors

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inventor(s); 1st						
1 st :	Mar Maraja	Date: 2206 7004				
	$A \cup C$ $A \cap C$	Date: 27.06.7004				
3 rd :	David W. Will.	Date: 25.08.200 4				
5 th :	Takas Manu	Date: 2462004				
	Mans hatt	Date: <u>23.06, 700</u> 4	I T			

RECORDED: 09/21/2004 REEL: 015154 FRAME: 0304